FPP29
Based on 1 Customer Validation
FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.20%
- Formel: C145H228N56O32
- Molecular Weight:3267.72
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Peptide Library
HY-L105
-
PROTAC Library
HY-L151
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Peptide Compound Library
HY-L105S
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Alle PROTACs Isoform-spezifische Produkte anzeigen
MoreAlle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
VHL |
FPP29 (24 h) potently inhibits the viability of HCCLM3 cells, with an IC50 of 3.65 μM after 24 h of incubation[1].
FPP29 (4 μM; 24-48 h) significantly inhibits the migration ability of HCCLM3 cells[1].
FPP29 (2-8 μM; 24 h) induces dose-dependent apoptosis in HCCLM3 cells following 24 h of incubation at concentrations of 2 μM, 4 μM, and 8 μM[1].
FPP29 (2-8 μM; 6-48 h) downregulates the protein expression of FOXM1, cyclin B1 and CDC25B in HCCLM3 cells, and regulates epithelial-mesenchymal transition markers in a dose-dependent and time-dependent manner (upregulating E-cadherin and downregulating N-cadherin)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma HCCLM3 cells
-
Concentration:4 μM
-
Incubation Time:24 h, 48 h
-
Result:Significantly inhibited HCCLM3 cell migration at 24 h and 48 h compared to the control, with statistical significance.
-
Cell Line:human hepatocellular carcinoma HCCLM3 cells
-
Concentration:2-8 μM
-
Incubation Time:24 h
-
Result:Induced apoptosis in HCCLM3 cells in a dose-dependent manner; the number of yellow-green/orange apoptotic cells increased with increasing FPP29 concentrations.
-
Cell Line:human hepatocellular carcinoma HCCLM3 cells
-
Concentration:2-8 μM (24 h incubation); 4 μM (6 h, 12 h, 24 h, 48 h incubation)
-
Incubation Time:24 h (dose-dependent); 6 h, 12 h, 24 h, 48 h (time-dependent)
-
Result:Reduced protein expression of FOXM1, cyclin B1, and CDC25B in both dose-dependent (0-8 μM, 24 h) and time-dependent (4 μM, 0-48 h) manners.
Increased E-cadherin protein expression and decreased N-cadherin protein expression in a dose-dependent manner (0-8 μM, 24 h).
| Species | Dose | Route | Tmax | T1/2 |
|---|---|---|---|---|
| Mice[1] | 20 mg/kg | i.v. | 0.25 h | 1.04 h |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (6-week-old male, subcutaneous xenograft model)[1]
-
Dosage:7.5 mg/kg; 15 mg/kg
-
Administration:intra-tumoral injection
-
Result:Inhibited tumor growth by 55%.
Inhibited tumor growth by 75%.
Reduced tumor weight in a dose-dependent manner.
Downregulated FOXM1 protein levels in tumor tissues in a dose-dependent manner.
Increased tumor necrosis and inflammatory cell infiltration.
Reduced Ki-67-positive proliferating cells.
Significantly increased TUNEL-positive apoptotic cells.
Caused no significant changes in mouse body weight, major organ histopathology, liver function tests, or blood routine indices.
Chemical Information
-
Appearance Solid
-
Molecular Weight 3267.72
-
Formel C145H228N56O32
-
Color White to off-white
-
Sequence
Ala-Trp-Trp-Asn-Thr-Glu-Trp-Gly-Ser-Ala-Leu-Ala-Pro-Tyr-Ile-Pro-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg
-
Sequence Shortening
AWWNTEWGSALAPYIPRRRRRRRRR
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
DMSO : 25 mg/mL (7.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3060 mL | 1.5301 mL | 3.0602 mL | 7.6506 mL |
| 5 mM | 0.0612 mL | 0.3060 mL | 0.6120 mL | 1.5301 mL |
FPP29 Related Classifications
HY-P11228 Related Classifications
Powered by Bioz